{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:48:34Z","timestamp":1789213714825,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangzhou Basic and Applied Basic Research","award":["2023A041765"],"award-info":[{"award-number":["2023A041765"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024A1515011150"],"award-info":[{"award-number":["2024A1515011150"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024A1515012975"],"award-info":[{"award-number":["2024A1515012975"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["\uff08Y-2024AZ(BTK)QN- -0062\uff09"],"award-info":[{"award-number":["\uff08Y-2024AZ(BTK)QN- -0062\uff09"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary mediastinal B-cell lymphoma (PMBCL) patients who achieve a complete response (CR) following first-line immunochemotherapy tend to have favorable outcomes, even without subsequent radiotherapy (RT). However, it remains unclear whether the survival of patients who do not achieve CR after first-line therapy and subsequently receive radiotherapy is comparable to that of CR patients who undergo observation alone. To address this gap, we conducted a systematic review and meta-analysis to compare progression-free survival (PFS) and overall survival (OS) between CR patients who forgo radiotherapy and non-CR patients who receive consolidative radiotherapy. Additionally, we examined potential influencing factors to provide evidence-based guidance for clinical treatment strategies.\u00a0A comprehensive search of multiple databases (PubMed, EMBASE, and Cochrane Library) was conducted for the period from January 1, 2012, to September 1, 2024. Using predefined keywords and screening procedures, 15 studies were ultimately included. The primary endpoint was PFS, with OS as a secondary endpoint. Subgroup analyses were performed based on chemotherapy regimens.\u00a0This systematic review and meta-analysis of 15 studies demonstrated that consolidative radiotherapy significantly improves PFS in patients with partial remission (PR) after first-line immunochemotherapy, with an overall risk ratio (RR) of 1.11 (95% confidence interval [CI]: 1.05\u20131.16). For OS, the RR was 1.04 (95% CI: 0.97\u20131.12), crossing the line of no effect, which suggests that consolidative radiotherapy does not have a statistically significant impact on OS.\u00a0Consolidative radiotherapy improves PFS in patients with PMBCL, but its effect on OS is not statistically significant.<\/jats:p>","DOI":"10.1007\/s00277-025-06530-8","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:36:01Z","timestamp":1758764161000},"page":"4611-4623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients"],"prefix":"10.1007","volume":"104","author":[{"given":"Dongyu","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"6530_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(02)00714-3","volume":"3","author":"TF Barth","year":"2002","unstructured":"Barth TF, Leithauser F, Joos S, Bentz M, Moller P (2002) Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 3:229\u2013234","journal-title":"Lancet Oncol"},{"key":"6530_CR2","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.1999.17.8.2479","volume":"17","author":"PC Bishop","year":"1999","unstructured":"Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC (1999) CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 17:2479\u20132485","journal-title":"J Clin Oncol"},{"key":"6530_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"issue":"3","key":"6530_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/annonc\/mdq418","volume":"22","author":"M Rieger","year":"2011","unstructured":"Rieger M, \u00d6sterborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD (2011) Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera international trial group study. Ann Oncol 22(3):664\u2013670","journal-title":"Ann Oncol"},{"issue":"2","key":"6530_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","volume":"17","author":"TP Vassilakopoulos","year":"2012","unstructured":"Vassilakopoulos TP et al (2012) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist Vol 17(2):239\u2013249","journal-title":"Oncologist Vol"},{"issue":"1359","key":"6530_CR6","first-page":"22","volume":"17","author":"K Lisenko","year":"2017","unstructured":"Lisenko K et al (2017) Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC cancer 17(1359):22","journal-title":"BMC cancer"},{"key":"6530_CR7","doi-asserted-by":"publisher","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","volume":"27","author":"U Vitolo","year":"2016","unstructured":"Vitolo U et al (2016) Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol Vol 27:v91\u2013v102","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol Vol"},{"issue":"5","key":"6530_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1634\/theoncologist.11-5-488","volume":"11","author":"KJ Savage","year":"2006","unstructured":"Savage KJ (2006) Primary mediastinal large B-cell lymphoma. Oncologist 11(5):488\u2013495. https:\/\/doi.org\/10.1634\/theoncologist.11-5-488","journal-title":"Oncologist"},{"issue":"2","key":"6530_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","volume":"90","author":"G Todeschini","year":"2004","unstructured":"Todeschini G et al (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B\/VACOP-B. Br J Cancer Vol 90(2):372\u2013376. https:\/\/doi.org\/10.1038\/sj.bjc.6601460","journal-title":"Br J Cancer Vol"},{"issue":"4","key":"6530_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/bjh.14287","volume":"175","author":"M Gleeson","year":"2016","unstructured":"Gleeson M et al (2016) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol Vol 175(4):668\u2013672","journal-title":"Br J Haematol Vol"},{"issue":"11","key":"6530_CR11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/ajh.24172","volume":"90","author":"S Giri","year":"2015","unstructured":"Giri S et al (2015) Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis. Am J Hematol 90(11):1052\u20131054. https:\/\/doi.org\/10.1002\/ajh.24172","journal-title":"Am J Hematol"},{"issue":"1","key":"6530_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","volume":"92","author":"CC Pinnix","year":"2015","unstructured":"Pinnix CC et al (2015) Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiation Oncol Biology Phys Vol 92(1):113\u2013121. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.006","journal-title":"Int J Radiation Oncol Biology Phys Vol"},{"issue":"1","key":"6530_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.09.017","volume":"94","author":"MW Jackson","year":"2016","unstructured":"Jackson MW et al (2016) Improved survival with radiation therapy in stage I-II primary mediastinal B cell lymphoma: A surveillance, epidemiology, and end results database analysis. Int J Radiation Oncol Biology Phys Vol 94(1):126\u2013132. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.09.017","journal-title":"Int J Radiation Oncol Biology Phys Vol"},{"key":"6530_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. New Engl J Med Vol 368:1408\u20131416","journal-title":"New Engl J Med Vol"},{"key":"6530_CR15","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood.v99.8.2685","volume":"99","author":"WH Wilson","year":"2002","unstructured":"Wilson WH et al (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99:2685\u20132693. https:\/\/doi.org\/10.1182\/blood.v99.8.2685","journal-title":"Blood"},{"issue":"3","key":"6530_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3109\/10428194.2015.1067700","volume":"57","author":"MS Binkley","year":"2016","unstructured":"Binkley MS et al (2016) A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma Vol 57(3):604\u2013608. https:\/\/doi.org\/10.3109\/10428194.2015.1067700","journal-title":"Leuk Lymphoma Vol"},{"key":"6530_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"2","key":"6530_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/ejh.13715","volume":"108","author":"AC Freitas","year":"2022","unstructured":"Freitas AC et al (2022) End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: prognostic indicator and implications for consolidation radiotherapy. Eur J Haematol Vol 108(2):118\u2013124. https:\/\/doi.org\/10.1111\/ejh.13715","journal-title":"Eur J Haematol Vol"},{"issue":"24","key":"6530_CR19","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1182\/blood.2019004296","volume":"136","author":"AR Hayden","year":"2020","unstructured":"Hayden AR et al (2020) Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 136(24):2803\u20132811. https:\/\/doi.org\/10.1182\/blood.2019004296","journal-title":"Blood"},{"key":"6530_CR20","doi-asserted-by":"publisher","unstructured":"Franco C et al (2024) Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results. J Clin Oncol 42(34). https:\/\/doi.org\/10.1200\/JCO-24-01373","DOI":"10.1200\/JCO-24-01373"},{"issue":"7","key":"6530_CR21","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1097\/HS9.0000000000000917","volume":"7","author":"G Held","year":"2023","unstructured":"Held G et al (2023) Radiation and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: subgroup analysis of the UNFOLDER trial. Hema Sphere 7(7):e917. https:\/\/doi.org\/10.1097\/HS9.0000000000000917","journal-title":"Hema Sphere"},{"issue":"21","key":"6530_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood.V120.21.303.303","volume":"120","author":"J Kerry","year":"2012","unstructured":"Kerry J, Savage PR, Yenson T, Shenkier R, Klasa D, Villa O, Goktepe C, Steidl GW, Slack RD, Gascoyne JM, Connors, Laurie H (2012) Sehn; the outcome of primary mediastinal large B-Cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 120(21):303","journal-title":"Blood"},{"issue":"5","key":"6530_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L et al (2017) Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol Vol 179(5):739\u2013747. https:\/\/doi.org\/10.1111\/bjh.14951","journal-title":"Br J Haematol Vol"},{"key":"6530_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","volume":"60","author":"M Messmer","year":"2019","unstructured":"Messmer M et al (2019) R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Leuk Lymphoma Vol 60:1261\u20131265. https:\/\/doi.org\/10.1080\/10428194.2018.1519812","journal-title":"Leuk Lymphoma Vol"},{"issue":"17","key":"6530_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","volume":"32","author":"M Martelli","year":"2014","unstructured":"Martelli M et al (2014) [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin oncology: official J Am Soc Clin Oncol 32(17):1769\u20131775. https:\/\/doi.org\/10.1200\/JCO.2013.51.7524","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"4","key":"6530_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN et al (2018) R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 180(4):534\u2013544. https:\/\/doi.org\/10.1111\/bjh.15051","journal-title":"Br J Haematol"},{"issue":"4","key":"6530_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/hon.2172","volume":"33","author":"PL Zinzani","year":"2015","unstructured":"Zinzani PL et al (2015) The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol Vol 33(4):145\u2013150. https:\/\/doi.org\/10.1002\/hon.2172","journal-title":"Hematol Oncol Vol"},{"issue":"1","key":"6530_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clml.2023.08.021","volume":"24","author":"S Li","year":"2024","unstructured":"Li S et al (2024) Outcomes of patients treated with RCHOP with a PET-adapted approach for consolidative radiotherapy: a retrospective single-center study at the royal marsden hospital. Clin Lymphoma, Myeloma & Leukemia 24(1):48\u201354. https:\/\/doi.org\/10.1016\/j.clml.2023.08.021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"6530_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/leu.2015.120","volume":"30","author":"TP Vassilakopoulos","year":"2016","unstructured":"Vassilakopoulos TP et al (2016) PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia 30(1):238\u2013242. https:\/\/doi.org\/10.1038\/leu.2015.120","journal-title":"Leukemia"},{"issue":"9","key":"6530_CR30","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00277-021-04421-2","volume":"100","author":"TP Vassilakopoulos","year":"2021","unstructured":"Vassilakopoulos TP et al (2021) Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Annals Hematol Vol 100(9):2279\u20132292. https:\/\/doi.org\/10.1007\/s00277-021-04421-2","journal-title":"Annals Hematol Vol"},{"issue":"12","key":"6530_CR31","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3324\/haematol.2014.111203","volume":"99","author":"T Aoki","year":"2014","unstructured":"Aoki T et al (2014) Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica 99(12):1817\u201325. https:\/\/doi.org\/10.3324\/haematol.2014.111203","journal-title":"Haematologica"},{"issue":"5","key":"6530_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/10245332.2016.1258846","volume":"22","author":"X Liu","year":"2017","unstructured":"Liu X et al (2017) A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Hematol (Amsterdam Netherlands) Vol 22(5):258\u2013264. https:\/\/doi.org\/10.1080\/10245332.2016.1258846","journal-title":"Hematol (Amsterdam Netherlands) Vol"},{"issue":"5","key":"6530_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol Vol 25(5):571\u2013578. https:\/\/doi.org\/10.1200\/JCO.2006.08.2305","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol Vol"},{"issue":"5","key":"6530_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol Vol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol Vol"},{"issue":"6","key":"6530_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"A Gallamini","year":"2014","unstructured":"Gallamini A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99(6):1107\u20131113. https:\/\/doi.org\/10.3324\/haematol.2013.103218","journal-title":"Haematologica"},{"issue":"6","key":"6530_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5114\/wo.2015.56388","volume":"19","author":"I Petkovi\u0107","year":"2015","unstructured":"Petkovi\u0107 I (2015) Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn) 19(6):428\u2013435. https:\/\/doi.org\/10.5114\/wo.2015.56388","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"6530_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jcpt.13007","volume":"44","author":"J Li","year":"2019","unstructured":"Li J et al (2019) In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 44(6):875\u2013882. https:\/\/doi.org\/10.1111\/jcpt.13007","journal-title":"J Clin Pharm Ther"},{"issue":"22","key":"6530_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.V128.22.469.469","volume":"128","author":"WH Wilson","year":"2016","unstructured":"Wilson WH, Sin-Ho J, Pitcher BN et al (2016) Phase III randomized study of R\u2010CHOP versus DA\u2010EPOCH\u2010R and molecular analysis of untreated diffuse large B\u2010cell lymphoma: CALGB\/Alliance 50303. Blood 128(22):469. https:\/\/doi.org\/10.1182\/blood.V128.22.469.469","journal-title":"Blood"},{"issue":"1","key":"6530_CR39","doi-asserted-by":"publisher","first-page":"e3247","DOI":"10.1002\/hon.3247","volume":"42","author":"M Picardi","year":"2024","unstructured":"Picardi M et al (2024) Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal Gray zone lymphoma. Hematol Oncol Vol 42(1):e3247. https:\/\/doi.org\/10.1002\/hon.3247","journal-title":"Hematol Oncol Vol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06530-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:11Z","timestamp":1761283811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06530-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6530"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06530-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived, since this was a retrospective study, which did not include identifiable personal data or procedures other than those performed during the routine clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}